Picture loading failed.

Anti-ANGPT2;VEGFA therapeutic antibody (Pre-made Vanucizumab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-612-1mg 1mg 3090
GMP-Bios-ab-612-10mg 10mg 21890
GMP-Bios-ab-612-100mg 100mg 148000
GMP-Bios-ab-612-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ANGPT2;VEGFA therapeutic antibody (Pre-made Vanucizumab biosimilar,Bispecific mAb)
INN Name Vanucizumab
TargetANGPT2;VEGFA
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda;Kappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ
99% SI StructureNone;None
95-98% SI StructureNone;6bft:AB:HL/1cz8:HL:YX
Year Proposed2014
Year Recommended2015
CompaniesRoche
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours;Colorectal cancer
Development Techna